Paget disease of bone neurologic complications …

Neeraj Kumar MD

General Neurology

Updated 07.03.2023
Released 07.17.2000
Expires For CME 07.03.2026

Paget disease of bone: neurologic complications

Author: Neeraj Kumar MD

See Contributor Disclosures

Editor: Amy A Pruitt MD

Paget disease of bone: neurologic complications

In This Article

Quick Link

Introduction

Overview

Paget disease of bone is an osteoclastic-mediated disorder of the bone in which abnormal bone resorption and inadequate remodeling leads to mechanically weakened bone. Demonstrating variable geographic prevalence, it is becoming less frequent, and age of onset is lengthening in areas of high prevalence. A combination of genetic and environmental triggers appears to describe its pathophysiology and is helping to clarify other inherited osteolytic disorders of bone and their related cellular processes. In this article, the author provides the recommendations from the PRISM study and PRISM-EZ study with respect to symptomatic versus intensive treatment of Paget disease of bone with bisphosphonates. Concerns over the safety issues with bisphosphonate therapy are also addressed.

Key points

	• Paget disease of bone (PDB) is a disorder of bone remodeling where abnormal bone resorption and inadequate remodeling results in mechanically weakened bone.
	• Paget disease of bone is asymptomatic in over 70% of individuals and often identified incidentally by an elevated serum alkaline phosphatase or screening plain films of the abdomen.
	• Paget disease of bone demonstrates variable geographic prevalence, highest in Northwestern Europe, but is becoming less frequent in areas of once-high prevalence that predate current treatments.
	• Neurologic syndromes of Paget disease of bone result from the close relationship between the skeletal and nervous system, and although direct compression explains most observed syndromes, vascular steal phenomena may also play a role.
	• The primary intervention for Paget disease of bone is bisphosphonate treatment, after calcium and vitamin D deficiencies are corrected; zoledronate may be the treatment of first choice.

Historical note and terminology

Although Wilks described the disorder in 1869 (81), Sir James Paget’s publication of a necropsy report as a form of “chronic inflammation of the bones” (osteitis deformans) provided the first thorough description of the disorder (50); by 1889 the disorder was officially associated with Paget when the eponym, Paget disease of bone (PDB), was added to the Oxford English Dictionary. In his original report, Paget described a man who presented with thigh pain and tibial deformity and died 22 years later from a malignant tumor of the radius (09). Paget later published additional cases that with his original report identified many of the clinical and pathological features we now recognize (51). However, his suggestion of an inflammatory etiology has not been shown to be true.

Clinical manifestations

Presentation and course

Paget disease of bone is a focal disorder where the normal relationship between the continuous remodeling of bone by resorption and reformation is disrupted. Increased bone resorption with increased but abnormal bone reformation results in a disorganized mechanical structure and formation of thickened and structurally weakened bone (“mosaic” pattern of lamellar bone). The most common sites of involvement are the pelvis, lumbar spine, and femur, which are involved in more than 75% of cases; polyostotic disease is a more common occurrence than monostotic. The predilection for involvement of the vertebrae and the skull (skull involvement has a lower prevalence in men) is reflected by the potential for neurologic complications involving the spinal cord, cauda equina or spinal nerves, cranial nerves, and brain (33; 64; 56; 21; 02; 07).

Paget disease of bone is asymptomatic in over 70% of affected patients. Major clinical features include bone pain, deformity, pathological fracture, secondary osteoarthritis, and deafness. Less common are spinal stenosis and nerve compression syndromes, and rarely encountered are hypercalcemia, hydrocephalus, paraplegia, cardiac failure, and osteosarcoma (57; 56). The neurologic syndromes of Paget disease of bone result from the close relationship between the skeletal and nervous system. They can be classified as those originating from involvement of the skull or the spine (64; 21). Direct compression of nervous tissue explains most observed syndromes, but vascular steal phenomena as blood flow is rediverted to the highly vascular bone of skull or spine and may play a role (41).

The diagnosis of Paget disease of bone begins with a careful history and examination, supported by laboratory studies (elevated total alkaline phosphatase), with subsequent x-ray and bone scintigraphy establishing the diagnosis. Further radiological evaluation may be necessary with CT or MRI but is dictated by history and examination and not routinely performed.

Paget disease of bone (lateral skull x-rays)

(A) A lateral skull x-ray demonstrating the well defined large area of radiolucency representing the edge of an osteolytic margin (identified by the arrowheads) in Paget disease of bone calvarial involvement; these changes are ref...
Paget disease of bone (bone scan)

This technetium-99 bone scintigraphy study identifies areas of increased uptake within common sites of bone involvement in Paget disease of bone, pelvis, and spine, but tibial involvement occurs less frequently. (Bone scan provide...

In the setting of known Paget disease of bone, no neurologic syndromes are specific for the disorder. However, the presence of hearing loss or clinical features that suggest basilar impression, atlantoaxial instability, or spinal cord or nerve root syndromes suggest a possible relationship. Otherwise, it is best to consider Paget disease of bone as only one possible etiology for neurologic symptoms, and it is prudent to develop a complete differential diagnosis in each particular case.

Involvement of the skull leads to deformities of the skull base, narrowing of cranial nerve foramina, involvement of the cochlear capsule, and hypemia of the skull (41). Reported symptoms include headache, cranial neuropathies, dementia, parkinsonism (29), seizures, hydrocephalus, and a brainstem syndrome (06; 54), but the casual relationships are not always clear. The headache is often occipital, severe, and aggravated by coughing, sneezing, or straining (18) and may be secondary to basilar impression or a vascular steal phenomenon (41).

Paget disease of bone involvement of the base of the skull can affect the craniovertebral junction, which comprises the occiput, atlas, axis articulations, and ligaments; these structures enclose the cervicomedullary junction and lower four cranial nerves. Symptoms develop when the vertebral column becomes situated at an abnormally high level with respect to the skull base or basilar impression (or acquired basilar invagination). Symptoms and signs appear as neural structures are compromised, usually slowly and insidiously, manifested as dysfunction of brainstem, cerebellum, lower cranial nerves, cervical spinal cord, or upper cervical roots. Clinical findings include occipital headache, myelopathic motor and sensory deficits, brainstem or cerebellar signs, lower cranial nerve dysfunction, and at times evidence of vascular compromise (41). Hydrocephalus can develop as a result of basilar impression, presenting with clinical features of normal pressure hydrocephalus and responding to ventriculoperitoneal shunting (63). These skeletal changes of Paget disease of bone require careful consideration prior to surgery in regard to intubation, head positioning, and potential for excessive bleeding from hypervascularity of bone.

Hearing loss is a frequent feature of Paget disease of bone with skull involvement, prominent in 54.7% (control 20%), but likely underreported (05;40:189-93." data-code="PMID 16962839" data-url="https://www.ncbi.nlm.nih.gov/pubmed/16962839">84). Tinnitus is more frequent and obvious with increasing hearing impairment (38). The majority of patients demonstrate a high-frequency sensorineural hearing loss with low frequency air-bone gap. A continuous loss of bone mineral density of the cochlear capsule in Paget disease of bone explains both of those observations, possibly through disruption between mechanical and electrical sensory transduction; neither involvement of the ossicular chain nor compression of the acoustic nerve has been consistently demonstrated (44).

Other than hearing loss, cranial nerve deficits are uncommon and are frequently anecdotal in their reporting, with a crude relative risk of 1.2 with a 95% CL of 0.7 to 2.1 (05). Blindness is rare, but narrowing of the optic foramina can lead to optic atrophy (06), and papilledema may be evident if there is associated hydrocephalus. Anosmia can develop from involvement of the cribriform plate and ophthalmoplegia from nerve compression at the supraorbital fissure or petrous apex (52). Proptosis and enophthalmos may result from a disproportionate increase in the cranium compared to the ocular bones (26). Trigeminal neuralgia with hemifacial spasm (19), facial paralysis, bulbar palsy with dysphagia, and weakness of the sternocleidomastoid, trapezius, and tongue have been reported (41).

The possible causes of an acute cranial epidural hematoma, rare in the elderly, in the pagetoid skull following minimal head trauma include: (1) pathologic fracture due to pagetic changes of the skull, (2) hypervascularity of pagetic bone, (3) loosened dural adhesion to the internal table of the skull, and (4) a decreased tamponading effect to the developing epidural hematoma due to age-related atrophy of the brain (30). Epidural hematoma has been described in the spine with resulting cauda equina syndrome (62).

The spine is the second most common site of involvement, leading to an increased incidence of back pain, with the reported incidence ranging from 11% to 43% (24). Care must be exercised in attributing back pain to Paget disease alone because back pain solely attributed to Paget disease occurs in only 12% to 24% of cases with spine involvement. In the remainder of cases, arthritic or coexisting arthritic processes are responsible (22). The pain associated with Paget disease of bone is different than mechanical or arthritic pain and reflects different or multiple etiologies. It tends to be described as a deep, dull ache, unrelated to activity and not relieved by rest, sleep, or non-steroidal medications.

Paget disease of bone spine involvement is present at one or more sites in the majority of patients. Lumbar (54%) or thoracic (44%) sites are more frequently involved than cervical (15%) (33). Neurologic compromise remains uncommon but occurs more frequently with involvement of the thoracic or cervical spine. Perhaps the relatively larger lumbar central canal is responsible for this selectivity (22). Vertebral body compression fracture is the most common complication involving the spine and presents with the sudden onset of back pain, frequently at the lumbar site.

In one third of patients with spine involvement, symptoms of spinal stenosis may develop (24). The presentation of spinal stenosis with neurologic manifestations shows no pattern specific for Paget disease of bone. Lateral spinal stenosis could result in a radicular syndrome with the accompanying clinical features. Central stenosis may present as cauda equina, conus medullaris, or as a syndrome of neurogenic claudication while at the thoracic or cervical spine level, a myelopathic presentation may be seen. At times, a slowly progressive myelopathic presentation may not correspond to a demonstrable compressive lesion but may respond to medical treatment, suggesting either a decrease in soft-tissue swelling or reversal of a redistribution of blood flow from a “vascular steal” (41). Atlantoaxial instability from an underlying odontoid fracture is an uncommon but serious presentation (66).

Although a rare occurrence, the development of a sarcoma should be considered in the setting of a progressive deficit, increasing pain, or swelling. In such settings, further neurologic evaluation is necessary and by necessity may include MRI or CT imaging of the involved site.

Prognosis and complications

The prognosis of Paget disease of bone has markedly improved with the institution of bisphosphonate therapy, and neurologic complications may stabilize with medical therapy, but long-term prognosis remains unclear (07; 42). Rare complications such as hydrocephalus may improve with shunting, and advances in the surgical management of spine and atlantoaxial instability have also benefited Paget disease of bone patients. Non-skeletal neurologic complications from Paget disease of bone remain infrequent and population-based estimates suggest involvement of cranial nerves (0.4%), peripheral nerves (1.7%), nerve roots (3.8%), and basilar invagination (2.1%). Hearing loss was noted in 61% of patients (80), and although bisphosphonate therapy leads to a reduction in total alkaline phosphatase and might lessen tinnitus and vertigo, hearing loss may not improve (16).

Sarcomatous transformation of a pagetic bone (type of secondary osteosarcoma) is a rare occurrence that more often affects men, has a mean age at diagnosis of 66 years, and predominantly involves the axial skeleton (especially the pelvis); 88% of these were high grade osteosarcomas (15). Paget disease sarcomas were once believed to arise more often in polyostotic (78%) versus monostotic disease, but 42% to 47% of cases are now monostotic and may represent the initial manifestation of Paget disease of bone (15; 39). The current incidence of pagetic sarcoma in most series remains less than 1%, but despite advances in the treatment of primary osteosarcomas in children, there has been no similar significant improvement in outcome over the last several decades in Paget disease of bone, with a median survival of 0.67 years (39; 65).

A registry review of Paget sarcoma identified 13 patients with involvement of the spine (14.6%), 10 of whom were male with a median age of 66.9 years and with sacral and lumbar spine predominantly involved, but it remains a rare occurrence (69). As expected, their presentation was with increasing back and radicular pain accompanied by lower extremity weakness and autonomic dysfunction. Decompressive laminectomy (three patients) or radiotherapy (eight patients) treatments were instituted, but median survival was 4.2 months (0 to 13 months), and the predominant tumor was osteosarcoma.

Explanations for poor outcomes of sarcomas include limitation in chemotherapy administration by comorbidities within elderly patients, difficulty in its radiologic distinction from Paget disease of bone changes, and pre-existing pain or disability making malignant transformation less symptomatically obvious (39). Each of these contributes to the fact that at the time of diagnosis most tumors are at an advanced stage.

Clinical vignette

An 80-year-old, right-handed man presented with a brief episode of vertigo, which occurred as he rolled onto his right side when going to sleep and lasted seconds. His medical history included coronary artery disease (s/p CABG), hypertension, hyperlipidemia, and Paget disease of bone, which had been diagnosed earlier when he presented with bone pain and an elevated total alkaline phosphatase. Physical examination demonstrated only his hearing loss. Dix-Hallpike maneuver was negative. Laboratory evaluations included a normal CBC, ESR, and chemistry survey. Brain MRI described moderate chronic small vessel ischemic change in the deep white matter of either hemisphere; on MR angiography only mild to moderate mild basilar artery narrowing was seen. His audiogram demonstrated high-frequency sensorineural hearing loss bilaterally, worse on the right, but no low frequency air-bone gap. A diagnosis of benign positional vertigo was made, and his medical treatment for hypertension was further optimized while aspirin therapy was maintained.

This man’s hearing loss may have been secondary to his Paget disease of bone, but in light of the otherwise asymptomatic nature of his Paget disease, the lack of more prominent changes on radiological imaging, and normal total alkaline phosphatase level, no further interventions were undertaken (56; 68).

Biological basis

Etiology and pathogenesis

Although the etiology of Paget disease of bone is unknown, there is evidence for both genetic and environmental factors. Familial and sporadic subtypes are described. There are geographic differences in prevalence and an increasing prevalence with age but the overall prevalence and severity have decreased over the last 25 years (10). A positive family history is elicited in at least 15% of cases (36), and the risk of developing the disease in a relative of an affected person is 7 to 10 times greater than in the general population. In familial forms of Paget disease of bone, at least seven chromosomal regions or loci (PDB1 to PDB7) are described as containing a potential candidate gene, but only PDB-3 codes for a gene on chromosome 5q35, sequestosome 1 (SQSTM1). Mutations within SQSTM1 are identified in up to 40% of hereditary autosomal dominant Paget disease of bone cases and 10% of sporadic cases; the mutations may, however, predict individuals at risk of more severe disease (78; 58). Additional candidate genes that increase the risk of Paget disease of bone are being identified (01).

The primary cellular abnormality in Paget disease of bone is considered to arise from the osteoclast or its precursor, but abnormalities of the osteoblast and bone microenvironment suggest a more complicated pathogenesis (57). However, the osteoclast signaling pathway and in particular the receptor RANK (Receptor Activator of NF-Kappa B) on osteoclast precursors and its activating ligand, RANKL (secreted by stromal cells and osteoblasts), has the greatest relevance to Paget disease of bone and several related disorders. RANK/RANKL interaction leads to osteoclast activation and inhibition of osteoclastic apoptosis. The SQSTM1 gene encodes p62, a scaffolding protein that forms a complex with RANK and other proteins that after RANKL binding are important for the eventual downstream activation of several transcription factors including NF-κB. Mutations in the SQSTM1 gene affect its ubiquitin binding and through unclear mechanisms affect osteoclastic function (59).

Several rare genetic disorders share characteristics with Paget disease of bone: increased bone turnover, expansion, and deformity as well as alkaline phosphatase elevations (08). The allelic autosomal dominant disorder that affects the RANK protein (TNFRSF11A gene) by activating it is familial expansive osteolysis (expansile skeletal hyperphosphatasia or early-onset familial Paget disease). Onset is in childhood or early adulthood, tends to symmetrically involve the appendicular skeleton, and is associated with early deafness. An autosomal recessive disorder, juvenile Paget disease of bone (familial hyperphosphatasemia or idiopathic hyperphosphatasia) affects the protein osteoprotegerin (TNFRSF11B), a decoy receptor for RANKL. Onset is in infancy or early childhood; the whole skeleton is involved symmetrically; and deafness as well as retinal changes may occur. An autosomal disorder, IBMPFD (inclusion body myopathy, Paget disease of bone, and frontotemporal dementia) affects the VCP gene encoding the valosin-containing protein. Although it is involved in various cellular processes, one process is of relevance, ubiquitin-dependent protein degradation affecting NF-κB signaling through regulation of an associated protein, 1κB-alpha. The most typical presentation for IBMPFD is at a mean age of onset of 44 years and with a proximal myopathy. Muscle biopsy shows nonspecific myopathic changes with or without rimmed vacuoles consistent with inclusion bodies (77; 28). Patients may have typical features of Paget disease of bone (seen in 57%) and an elevated alkaline phosphatase, but the mean age of onset of these symptoms is earlier, at 40 years of age (34). A frontotemporal dementia with a mean age of onset of 57 years “completes” the triad, but the triad is found in only 27% of individuals. A report noted Paget disease in association with spastic paraparesis in a patient with a VCP mutation (47).

A viral etiology was suggested in Paget disease of bone after the identification of nucleocapsid-like structures within the nuclei and cytoplasm of osteoclasts; paramyxoviruses were suggested as the etiology (60). Because SQSTM1 and VCP genes play a role in the process of autophagy, these same inclusions may only represent abnormal degradation products or aggregates of cellular proteins (32; 56).

Three main phases of Paget disease of bone correspond to the “prominence” of either osteoclastic or osteoblastic activity: (1) the osteolytic phase where osteoclastic activity predominates and bone resorption (or absorption) occurs, (2) the mixed phase with a combination of osteoblastic and osteoclastic activity, and (3) the osteoblastic phase where new bone formation (apposition) occurs. The high bone turnover characteristic of Paget disease of bone is manifested as increased trabecular number (rather than thickness), resulting in an increase in cancellous bone volume and prominent fibrosis seen at the trabecular bone surface. The contributory role of osteoblast involvement is further highlighted within a quantitative histomorphometric review of biopsied cases. Using specific indices, the prominence of the resulting osteoid formation reflects increased osteoblast function rather than a mineralization defect (67). One other phase, inactive sclerotic phase where new osteoclastic and osteoblastic formation ceases, but the bone retains a sclerotic architecture, may represent “the” final stage (13).

Recognition of the initial lytic phase is dependent on the ratio between trabecular and cortical bone. When the ratio is low (skull, femur, and humerus) a clear lytic radiographic leading edge at the interface with normal bone is seen.

Paget disease of bone (lateral skull x-rays)

(A) A lateral skull x-ray demonstrating the well defined large area of radiolucency representing the edge of an osteolytic margin (identified by the arrowheads) in Paget disease of bone calvarial involvement; these changes are ref...

When the ratio is high (vertebra, sacrum, and pelvis) the lytic phase is not detected (13). All phases can otherwise be identified in the same patient and in different bones. An interesting observation is that while progression of disease occurs, new bone involvement, crossing of Paget disease of bone to adjacent bone or across joints, or “metastasis” to new sites is uncommon (33).

Neurologic complications can occur during any phase of the disease (54; McKloskey and Kanis 2002; 64). The mechanisms of neurologic compromise include: (1) direct compression of neurologic structures from expansion of bone (79), (2) ossification of adjacent structures (25; 27; 48), (3) pathologic fracture or subluxation, (4) epidural hematoma (17; 30; 62), (5) sarcomatous change (40), and (6) ischemia due to vascular steal (55; 85), or compression of the vascular supply to neurologic tissues.

Involvement of the spine in Paget disease of bone results in vertebral body expansion in the anterior-posterior and lateral dimensions, usually through periosteal apposition and endosteal absorption. Vertebral height remains unchanged as the vertebral endplates are subchondral condensations of trabecular bone, not true bony cortex, so they lack a periosteum or endosteum interface (13). This combination of apposition and absorption at the periosteal/endosteal surfaces of the anterior and posterior border results in trabecular bone hypertrophy and thickening of the end-plates of the vertebrae that results in a radiographic image referred to as “picture-frame” sign; progression to the sclerotic phase with an increased density of the vertebra body leads to a radiographic image of an “ivory vertebrae.” Involvement of the posterior neural arch elements causes further narrowing of the spinal canal through periosteal apposition and either endosteal apposition or absorption. Involvement of the adjacent soft tissue, cartilage, ligaments, and intervertebral disc (24) as well as extra-osseous extension can occur. Secondary bone marrow changes develop, but their variable expression on MRI may necessitate comparison to standard radiographs or CT images to exclude suspected Paget disease of bone.

The symptoms that result from spine involvement are attributable to vertebral expansion, facet joint arthritis, ligament ossification, spondylolisthesis, fracture, extra-osseous involvement, or an arterial steal syndrome (13). However, involvement of the spine in Paget disease of bone may be asymptomatic or the etiology of such symptoms unrelated. Rare causes of compression of the cord or cauda equina by ossification of the epidural fat and ligamentum flavum (25; 23; 27; 48) have been reported. Myelopathy has been described in Paget disease without evidence of compression (85) and with or without compression may respond completely to calcitonin or bisphosphonate therapy. Vascular steal may account for neurologic compromise in these patients. Blood flow in pagetic bone using 18F clearance in 14 patients ranged from 4.4% to 18.9% blood volume/min in patients with Paget disease compared to 4.4% to 5.9% in those without Paget disease of bone. The increase in skeletal blood flow correlated with increased levels of total alkaline phosphatase. Both fell towards normal after treatment with calcitonin (83).

Differential diagnosis

Paget disease of bone (lateral skull x-rays)

(A) A lateral skull x-ray demonstrating the well defined large area of radiolucency representing the edge of an osteolytic margin (identified by the arrowheads) in Paget disease of bone calvarial involvement; these changes are ref...
Paget disease of bone (bone scan)

This technetium-99 bone scintigraphy study identifies areas of increased uptake within common sites of bone involvement in Paget disease of bone, pelvis, and spine, but tibial involvement occurs less frequently. (Bone scan provide...

Management

Asymptomatic Paget disease of bone identified by radiographs or an elevated serum alkaline phosphatase currently does not require treatment but follow-up is advised. Treatment in Paget disease of bone has the short-term goal of reducing bone turnover and alleviation or prevention of symptoms from neurologic and skeletal complications, whereas the long-term goals are to prevent osteoarthritis and progression of the disease (70). Symptoms that require treatment include bone pain, back pain, pain from arthropathy, or neurologic symptoms such as headache, hearing loss, radiculopathy, spinal cord syndromes, or symptomatic basilar impression. Possible indications for medical intervention in asymptomatic individuals include hypercalcemia, age of onset less than 50 years of age, lesions in high-risk areas such as the cervical or thoracic spine, or elevated total alkaline phosphatase. Treatment may also be instituted prior to a planned orthopedic procedure to reduce hypervascularity to a pagetic site (14).

The general management of pain is with nonsteroidal anti-inflammatories and additional treatment regimens. Mechanical assistance such as canes and heel lifts may be used as needed.

The PRISM (Randomized trial of Intensive versus Symptomatic Management of Paget disease) treatment trial compared symptomatic treatment (administered to patients experiencing pain) to intensive treatment (administered to patients with or without pain) in regard to the beneficial effects of lowering the serum alkaline phosphatase as a marker of disease activity (75). Serum alkaline phosphatase levels were significantly lower in the intensive treatment group within 4 months of beginning treatment, but there was no difference in quality-of-life assessments, overall bodily pain, or in pagetic bone pain (37). The PRISM-EZ study was an extension of the PRISM study and investigated the long-term effects of a treatment strategy that aimed to normalize bone turnover with that of symptomatic treatment (72). It showed that long-term intensive bisphosphonate therapy did not provide clinical benefit over symptomatic therapy and was associated with a nonsignificant increase in the risk of fractures, orthopedic events, and serious adverse events. Based on these studies it has been suggested that bisphosphonate therapy in Paget disease of bone should focus on symptom control rather than suppression of bone turnover.

The primary modality of treatment of Paget disease of bone is with antiresorptive therapies and any of the FDA-approved treatments can be used. Bisphosphonates are now considered drugs of first choice although their ability to prevent long-term complications is currently unknown (20). Pamidronate, zoledronic acid, and risedronate are favored because of their greater effectiveness in reducing bone turnover, but although randomized trials are not yet available in regards to comparative effectiveness (57), zoledronate is becoming the treatment of first choice. Pamidronate and zoledronate can be administered intravenously but are associated with a flu-like reaction in 10% to 25% of patients. Risedronate may be associated with gastrointestinal side effects and requires fasting before its administration. A single infusion may have a long-term effect (61). Intramuscular neridronate may be an alternative to those unwilling to undergo intravenous therapy or intolerant of oral bisphosphonates (43). Bisphosphonate therapy should be avoided in renal impairment and limited safety data suggest it should also be avoided in pregnancy and lactation. Although bisphosphonate therapies are increasingly used, postmarketing surveillance has suggested different safety issues summarized in a review (71): 1) although the absolute risk of atypical femoral fracture is increased with long-term use, that risk is small; 2) osteonecrosis of the jaw is rare and more common in high-dose therapy used in oncology (82), but jaw pain can occur in Paget disease of bone; 3) risk of atrial fibrillation is negligible; and 4) a definite link to an increased risk of esophageal cancer is not established. Although not a formal recommendation, after 5 years consideration should be made to a drug holiday for those patients at low risk of fracture (71).

“Resistance” (biochemical or total alkaline phosphatase normalization) to one bisphosphonate does not indicate resistance to the class of drugs, and total alkaline phosphatase response may occur with another (31). Acquired resistance to the effectiveness of bisphosphonates has also been observed with pamidronate and with clodronate and may be related to vitamin D receptor gene polymorphisms (45), but this type of resistance has not yet been evident with zoledronate.

Dietary calcium and vitamin D deficiencies must be corrected prior to the use of any bisphosphonates to prevent hypocalcemia or focal osteomalacia.

The cost-effective way to evaluate the success of bisphosphonate therapy is with total alkaline phosphatase measured 3 months after therapy and a decision to retreat by a total alkaline phosphatase level at 6 months. Recurrence or persistence of symptoms, elevation of total alkaline phosphatase to 25% above normal, or the lowest nadir and reappearance of lytic lesions support consideration of retreatment (14). The newer intravenous bisphosphonates may allow the total alkaline phosphatase to be followed less often, every 6 to 12 months, due to their longer skeletal half-life. Pain may have alternate etiologies, and it alone may not necessarily support a therapeutic intervention, prior to investigation for other potential non-Paget disease of bone etiologies.

The most common indication for surgical treatment of Paget disease of bone is joint replacement for osteoarthritis, but other surgical procedures include fixation of a fracture or osteotomy. Paget disease of bone involvement of spine or skull may necessitate surgical intervention, but medical management may still be effective and an initial consideration. Therefore, aggressiveness of initial interventions needs to be tempered by severity and acuteness of the neurologic deficit. In select cases, spinal decompression to relieve compression of neural elements may be indicated (02).

CSF diversionary procedures for Paget disease related hydrocephalus may result in significant neurologic recovery (49).

Surgery or spinal complications are difficult due to involvement at multiple levels, vascular bone with problematic bleeding, and the older age group. A review of 62 published cases showed some degree of benefit in 82% but an 11% mortality rate and reoperation required in 9% (79). Medical management is still the preferred initial intervention, but there are benefits of newer techniques such as vertebroplasty (73). Careful preoperative assessment and attention to perioperative bleeding risks remains critical (53).

References

01: Albagha OM, Visconti MR, Alonso N, et al. Genome-wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget’s disease of bone. Nat Genet 2010;42:520-4. PMID 20436471
02: Al-Rashid M, Ramkumar DB, Raskin K, Schwab J, Hornicek FJ, Lozano-Calderon SA. Paget disease of bone. Orthop Clin North Am 2015;46(4):577-85. PMID 26410646
03: Altman RD, Bloch DA, Hochberg MC, Murphy WA. Prevalence of pelvic Paget's disease of bone in the United States. J Bone Miner Res 2000;15:461-5. PMID 10750560
04: Bastin S, Bird H, Gamble G, Cundy T. Paget’s disease of bone – becoming a rarity. Rheumatology 2009;48:1232-5. PMID 19608727
05: Bone HG. Nonmalignant complications of Paget’s disease. J Bone Miner Res 2007;21:P64-8. PMID 17229011
06: Chakravorty NK. Neurological complications of Paget's disease of bone. Br J Clin Pract 1985;39:335-8. PMID 4063128
07: Choi YJ, Sohn YB, Chung YS. Updates on Paget's disease of bone. Endocrinol Metab (Seoul) 2022;37(5):732-43. PMID 36327984
08: Chung PY, Van Hul W. Paget’s disease of bone: evidence for complex pathogenetic interactions. Semin Arthritis Rheum 2012;41(5):619-41. PMID 21959292
09: Colman E. Sir James Paget: the man and the eponym. Calcif Tissue Int 2002;70:430-1. PMID 11960206
10: Corral-Gudino L, Borao-Cengotita-Bengoa M, Del Pino-Montes J, Ralston S. Epidemiology of Paget’s disease of bone: a systematic review and meta-analysis of secular changes. Bone 2013;55(2):347-52. PMID 23643679
11: Cundy T, Bolland M. Paget disease of bone. Trends Endocrinol Metab 2008;19:246-53. PMID 18691901
12: Cundy T, Reid IR. Paget’s disease of bone. Clin Biochem 2012;45(1-2):43-8. PMID 22024254
13: Dell’Atti C, Cassar-Pullicino VN, Laiam RK, Tins BJ, Tyrrell PN. The spine in Paget’s disease. Skeletal Radiol 2007;36:609-26. PMID 17410356
14: Devogelaer JP, Bergmann P, Body JJ, et al. Management of patients with Paget’s disease: a consensus document of the Belgian Bone Club. Osteoporos Int 2008;19:1109-17. PMID 18504638
15: Deyrup AT, Montag AG, Inwards CY, Xu Z, Swee RG, Unni K. Sarcomas arising in Paget disease of bone: a clinicopathologic analysis of 70 cases. Arch Pathol Lab Med 2007;131:942-6. PMID 17550323
16: Donath J, Krasznai M, Fornet B, Gergely P, Poór G. Effect of bisphosphonate treatment in patients with Paget’s disease of the skull. Rheumatology 2004;43:89-94. PMID 12923287
17: Drapkin AJ. Epidural hematoma complicating Paget's disease of the skull: a case report. Neurosurgery 1984;14:211-4. PMID 6709145
18: Friedman P, Sklaver N, Klawans HL Jr. Neurologic manifestations of Paget's disease of the skull. Dis Nerv Syst 1971;32:809-17. PMID 5139203
19: Gardner WJ, Dohn DF. Trigeminal neuralgia-hemifacial spasm-Paget’s disease: significance of this association. Brain 1966;89:555-62. PMID 5921129
20: Gennari L, Merlotti D, Mossetti G, et al. The use of intravenous aminobisphosphonates for the treatment of Paget’s Disease of Bone. Mini Rev Med Chem 2009;9:1052-63. PMID 19689402
21: Gruener G, Camacho P. Paget’s disease of bone. In: Biller J, Ferro JM, editors. Handbook of clinical neurology, 3rd series. Amsterdam: Elsevier, 2014;119:529-40.
22: Hadjipavlou A, Gaitanis IN, Katonis PG, Lander P. Paget’s disease of the spine and its management. Eur Spine J 2001;10:370-84. PMID 11718191
23: Hadjipavlou A, Katonis PG, Tzermiadianos MN, Tsoukas GM, Sapkas G. Principles of management of osteometabolic disorders affecting the spine. Eur Spine 2003;12:S113-31. PMID 14505119
24: Hadjipavlou A, Lander P. Paget disease of the spine. J Bone Joint Surg Am 1991;73:1376-81. PMID 1833408
25: Hadjipavlou A, Shaffer M, Lander P, Srolovitz H. Pagetic spinal stenosis with extradural pagetoid ossification: a case report. Spine 1988;13:128-30. PMID 3381126
26: Hardy TG, McNab AA. Bilateral enophthalmos associated with Paget disease of the skull: a case report. Ophthal Plast Reconstr Surg 2002;18:388-90. PMID 12352829
27: Hepgul K, Nicoll JA, Coakham HB. Spinal cord compression due to pagetic spinal stenosis with involvement of the extradural soft tissues: a case report. Surg Neurol 1991;35:143-6. PMID 1846708
28: Iannibelli E, Gibertini S, Cheli M, et al. VCP-related myopathy: a case series and a review of literature. Acta Myol 2023;42(1):2-13. PMID 37091525
29: Ikeda K, Kinoshita M, Aoki K, Tomatsuri A. Hydrocephalic parkinsonism due to Paget's disease of bone: dramatic improvement following ventriculoperitoneal shunt and temporary levodopa/carbidopa therapy. Mov Disord 1997;12:241-2. PMID 9087985
30: Itoyama Y, Fukumura A, Ito Y, Matsukado Y. Acute epidural hematoma complicating Paget's disease of the skull. Surg Neurol 1986;25:137-41. PMID 3941981
31: Joshua F, Epstein M, Major G. Bisphosphonate resistance in Paget’s disease of bone. Arthritis Rheum 2003;48:2321-3. PMID 12905487
32: Ju JS, Weihl CC. Inclusion body myopathy, Paget’s disease of the bone and frontotemporal dementia: a disorder of autophagy. Hum Mol Genet 2010;19(R1):R38-45. PMID 20410287
33: Kanis J. Pathophysiology and treatment of Paget’s disease of bone. 2nd ed. London: Martin Dunitz, 1998.
34: Kimonis VE, Mehta SG, Fulchiero EC, et al. Clinical studies in Familial VCP myopathy associated with Paget’s disease of bone and frontotemporal dementia. Am J Med Genet Part A 2008;146A:745-57. PMID 18260132
35: Lalam RK, Cassar-Pullicino VN, Winn N. Paget disease of bone. Semin Musculoskelet Radiol 2016;20(3):287-99. PMID 27741544
36: Langston AL, Campbell MK, Fraser WD, Maclennan G, Selby P, Ralston SH. Clinical determinants of quality of life in Paget’s disease of bone. Calcif Tissue Int 2007;80:1-9. PMID 17205328
37: Langston AL, Campbell MK, Fraser WD, et al. Randomized trial of intensive bisphosphonate treatment versus symptomatic management in Paget’s Disease of Bone. J Bone Miner Res 2010;25:20-31. PMID 19580457
38: Mackenzie I, Young C, Fraser WD. Tinnitus and Paget’s disease of bone. J Laryngol Otol 2006;120:899-902. PMID 17040597
39: Mangham DC, Davie MW, Grimer RJ. Sarcoma arising in Paget’s disease of bone: declining incidence and increasing age at presentation. Bone 2009;44:431-6. PMID 19064007
40: Matsukuma S, Kawabata M, Takemoto T, Wada R, Kuwabara N. Paget sarcoma of the cervical vertebrae: an autopsy case report and review of the literature. Pathol Int 1995;45:885-9. PMID 8581154
41: McCloskey EV, Kanis JA. Neurological complications of Paget’s disease. Clin Rev Bone Min Metab 2002;1:135-43.
42: Merlotti D, Rendina D, Cavati G, et al. Drug treatment strategies for paget's disease: relieving pain and preventing progression. Expert Opin Pharmacother 2023;24(6):715-27. PMID 36961938
43: Merlotti D, Rendina D, Gennari L, et al. Comparison of intravenous and intramuscular neridronate regimens for the treatment of Paget Disease of Bone. J bone Miner Res 2011;26:512-8. PMID 20814970
44: Monsel EM. The mechanism of hearing loss in Paget’s disease of bone. Laryngoscope 2004;114:598-606. PMID 15064610
45: Mossetti G, Gennari L, Rendina D, et al. Vitamin D receptor gene polymorphisms predict acquired resistance to clodronate treatment in patients with Paget’s disease of bone. Calcif Tissue Int 2008;83:414-24. PMID 19020788
46: Murphy CM, Shorten G. Spinal anaesthesia in three patients with Paget’s disease of bone. Anaesthesia 1999;54:1227. PMID 10712178
47: Nakamura T, Kawarabayashi T, Koh K, Takiyama Y, Ikeda Y, Shoji M. Spastic paraplegia with Paget's disease of bone due to a VCP gene mutation. Intern Med 2021;60(1):141-4. PMID 32893227
48: Nicholson DA, Roberts T, Sanville PR. Spinal cord compression in Paget's disease due to extracranial pagetic ossification. Br J Radiol 1991;64:864-6. PMID 1913055
49: Omar AT 2nd, Sandoval MAS, Pascual JLR 3rd, Khu KJO. Management of hydrocephalus in Paget's disease of bone: systematic Review and Illustrative Case. World Neurosurg 2020;135:e640-9. PMID 31881339
50: Paget J. On a form of chronic inflammation of the bones (osteitis deformans). Med Chirurg Transl London 1877;60:37-63.
51: Paget J. Additional cases of osteitis deformans. Med Chirurg Transl London 1882;65:225-36.
52: Pane A. Paget disease manifesting with compressive sixth-nerve palsy that resolved with intravenous zoledronic acid therapy. Arch Opthalmol 2007;125(10):1440-1. PMID 17923566
53: Parvizi J, Klein GR, Sim FH. Surgical management of Paget’s disease if bone. J Bone Miner Res 2007;21:P75-82.
54: Poncelet A. The neurologic complications of Paget's disease. J Bone Miner Res 1999;14(Suppl 2):88-91. PMID 10510221
55: Porrini AA, Maldonado Cocco JA, Garcia Morteo O. Spinal artery steal syndrome in Paget's disease of bone. Clin Exp Rheumatol 1987;5:377-8. PMID 3440335
56: Ralston SH. Clinical practice. Paget’s disease of bone. N Engl J Med 2013;368(7):644-50. PMID 23406029
57: Ralston SH, Langston AL, Reid IR. Pathogenesis and management of Paget’s disease of bone. Lancet 2008;372:155-63. PMID 18620951
58: Ralston SH, Layfield R. Pathogenesis of Paget disease of bone. Calcif Tissue Int 2012;91(2):97-113. PMID 22543925
59: Rea SL, Walsh JP, Layfield R, Ratajczak T, Xu J. New insights into the role of sequestosome 1/p62 mutant proteins in the pathogenesis of Paget’s disease of bone. Endocr Rev 2013;34(4):501-24. PMID 23612225
60: Reddy SV. Etiologic factors in Paget’s disease of bone. Cell Mol Lif Sci 2006;63:391-8. PMID 16429324
61: Reid IR, Lyles K, Su G, et al. A single infusion of zoledronic acid produces sustained remission in Paget disease: data to 6.5 years. J Bone Miner Res 2011;26(9):2261-70. PMID 21638319
62: Richter RL, Semble EL, Turner RA, Challa VR. An unusual manifestation of Paget's disease of bone: spinal epidural hematoma presenting as acute cauda equina syndrome. J Rheumatol 1990;17:975-8. PMID 2213767
63: Roohi F, Mann D, Kula RW. Surgical management of hydrocephalic dementia in Paget’s disease of bone: the 6-year outcome of ventriculo-peritoneal shunting. Clin Neurol Neurosurg 2005;107:325-8. PMID 15885393
64: Rubin DJ, Levin RM. Neurologic complications of Paget disease of bone. Endocr Pract 2009;15(2):158-66. PMID 19289329
65: Ruggieri P, Calabro T, Montalti M, Mercuri M. The role of surgery and adjuvants to survival in Pagetic osteosarcoma. Clin Orthop Relat Res 2010;468:2962-8. PMID 20652460
66: Sawardekar UG, Nadimpalli SPR, Weisenberg E, Kranzler L. An unusual presentation of Paget disease: pathological fracture of the odontoid. J Neurosurg Spine 2008;9:3433-6. PMID 18939919
67: Seitz S, Priemel M, Zustin J, et al. Paget’s disease of bone: Histologic analysis of 754 patients. J Bone Miner Res 2009;24:62-9. PMID 18767930
68: Seton M. Paget disease of bone: diagnosis and drug therapy. Cleve Clin J Med 2013;80(7):452-62. PMID 23821690
69: Sharma H, Mehdi SA, MacDuff E, Reece AT, Jane MJ, Reid R. Paget sarcoma of the spine: Scottish bone tumor registry experience. Spine 2006;31:1344-50. PMID 16721297
70: Silverman SL. Paget disease of bone: therapeutic options. J Clin Rheumatol 2008;14:299-305. PMID 18838910
71: Suresh E, Pazianas M, Abrahamsen B. Safety issues with biphosphonate therpay for osteoporosis. Rheumatology (Oxford) 2014;53(1):19-31. PMID 23838024
72: Tan A, Goodman K, Walker A, et al. Long-term randomized trial of intensive versus symptomatic management in Paget's disease of bone: the PRISM-EZ study. J Bone Miner Res 2017;32(6):1165-73. PMID 28176386
73: Tancioni F, Di Leva A, Levi D, et al. Spinal decompression and vertebroplasty in Paget’s disease of the spine. Surg Neurol 2006;66:189-91. PMID 16876624
74: Theodorou DJ, Theodorou SJ, Kakitsubata Y. Imaging of Paget disease of bone and its musculoskeletal complications: review. AJR Am J Roentgenol 2011;196:S64-75. PMID 21606236
75: University of Aberdeen Health Services Research Unit. Randomized trial of intensive versus symptomatic management of Paget’s disease (PRISM). http://www.abdn.ac.uk. Accessed July 30, 2014.
76: van Staa TP, Selby P, Leufkens HG, Lyles K, Sprafka JM, Cooper C. Incidence and natural history of Paget’s disease of bone in England and Wales. J Bone Miner Res 2002;17:465-71. PMID 11878305
77: Viassolo V, Previtali SC, Schiatti E, et al. Inclusion body myopathy, Paget’s disease of the bone and frontotemporal dementia: recurrence of the VCP R155H mutation in an Italian family and implications for genetic counselling. Clin Genet 2008;74:54-60. PMID 18341608
78: Visconti MR, Langston AL, Alonso N, et al. Mutations of SQSTM1 are associated with severity and clinical outcome in Paget disease of Bone. J Bone Miner Res 2010;25:2368-73. PMID 20499339
79: Wallace E, Wong J, Reid IR. Pamidronate treatment of the neurologic sequelae of pagetic spinal stenosis. Arch Intern Med 1995;155:1813-5. PMID 7654117
80: Wermers RA, Tiegs RD, Atkinson EJ, Achenbach SJ, Melton LJ. Morbidity and mortality associated with Paget’s disease of Bone: A population-based study. J Bone Miner Res 2008;23:819-25. PMID 18269308
81: Wilks S. Case of osteoporosis or spongy hypertrophy of the bones (calvaria clavicle os femoris and rib exhibited at the Society). Trans Path Soc London 1869;20:273-7.
82: Wong PK, Borromeo GL, Wark JD. Bisphosphonate-related osteonecrosis of the jaw in non-malignant bone disease. Rheumatol Int 2013;33(9):2189-98. PMID 23652790
83: Wootton R, Reeve J, Spellacy E, Tellez-Yudilevich M. Skeletal blood flow in Paget's disease of bone and its response to calcitonin therapy. Clin Sci Mol Med 1978;54:69-74. PMID 620495
84: Young CA, Fraser WD, Mackenzie IJ. Detection of hearing impairment in Paget’s disease of bone using a simple scoring system: a case control study. Bone 2007;40:189-93. PMID 16962839
85: Yost JH, Spencer-Green G, Krant JD. Vascular steal mimicking compression myelopathy in Paget's disease of bone: rapid reversal with calcitonin and systemic steroids. J Rheumatol 1993;20:1064-5. PMID 8350315

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Neeraj Kumar MD

Dr. Kumar of the Mayo Clinic and the Mayo College of Medicine has no relevant financial relationships to disclose.
See Profile

Editor

Amy A Pruitt MD

Dr. Pruitt of the University of Pennsylvania School of Medicine has no relevant financial relationships to disclose.
See Profile

Former Authors

Ann Poncelet MD (original author) and Gregory Gruener MD MBA

Patient Profile

Age range of presentation: 19 to 65+ years
Sex preponderance: Male>female, >1:1
Heredity: Heredity may be a factor

The pattern described in many families is that of an autosomal dominant trait with incomplete penetrance. An autosomal recessive form of Paget disease (juvenile Paget disease) has also been described.
Population groups selectively affected: North Americans

Western Europeans
Occupation groups selectively affected: None selectively affected

ICD & OMIM codes

ICD-9: Paget disease of bone: 731.0
ICD-10: Paget’s disease of bone: M88

Paget’s disease of the skull: M88.0

Paget’s disease of other bones: M88.8

Paget’s disease of bone, unspecified: M88.9
OMIM: Paget disease of bone: #602080

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Paget disease of bone: neurologic complications

Associated Disorders

Cauda equina syndrome
High output cardiac failure
Osteoarthritis

Differential Diagnosis

Alzheimer disease
Multi-infarct dementia
Transient ischemic attack of the posterior circulation
Basilar invagination
Age-related arteriosclerosis
- Sensorineural hearing loss
- Osteoarthritis
- Disc disease
- Symptomatic cervical and lumbosacral stenosis
- Sarcoma

Paget disease of bone neurologic complications …

Paget disease of bone: neurologic complications

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Special considerations

Pregnancy

Anesthesia

Media

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Brain death/death by neurologic criteria

Hepatic encephalopathy

Bowel dysfunction in neurologic disorders

Coma due to primary brainstem and diencephalic lesions

Transient visual loss

Neuroimaging in acute stroke

Sports activities: neurologic complications

Neurotechnology: brain-computer and brain-machine interfaces

Paget disease of bone: neurologic complications

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Clinical vignette

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Diagnostic workup

Management

Special considerations

Pregnancy

Anesthesia

Media

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Brain death/death by neurologic criteria

Hepatic encephalopathy

Bowel dysfunction in neurologic disorders

Coma due to primary brainstem and diencephalic lesions

Transient visual loss

Neuroimaging in acute stroke

Sports activities: neurologic complications

Neurotechnology: brain-computer and brain-machine interfaces

This is an article preview.
Start a Free Account
to access the full version.